Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with
multiple therapeutic avenues to lower amyloid-β burden in Alzheimer's disease (AD). In
response to concerns raised by the Food and Drug Administration, the Alzheimer's
Association Research Roundtable convened a working group to review the publicly
available trial data, attempts at developing animal models, and the literature on the natural
history and pathology of related conditions. The spectrum of ARIA includes signal …